Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 30 October 1987:
Vol. 238. no. 4827, pp. 669 - 671
DOI: 10.1126/science.2960019
Prev | Table of Contents | Next

Articles

Science, Vol 238, Issue 4827, 669-671
Copyright © 1987 by American Association for the Advancement of Science

articles

Gene dosage of the amyloid beta precursor protein in Alzheimer's disease

MB Podlisny, G Lee, and DJ Selkoe

Department of Neurology, Harvard Medical School, Boston, MA 02115.

The progressive deposition in the human brain of amyloid filaments composed of the amyloid beta protein is a principal feature of Alzheimer's disease (AD). Densitometric analysis of Southern blots probed with a complementary DNA for the amyloid protein has been carried out to determine the relative dosage of this gene in genomic DNA of 14 patients with AD, 12 aged normal subjects, and 10 patients with trisomy 21 (Down syndrome). Whereas patients in the last group showed the expected 1.5-fold increase in dosage of this gene, none of the patients with AD had a gene dosage higher than that of the normal controls. These results do not support the hypothesis that the genetic defect in AD involves duplication of a segment of chromosome 21 containing the amyloid gene. Alternative mechanisms for the brain-specific increase in amyloid protein deposition in AD should be considered.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.
X. Sun, Y. Tong, H. Qing, C.-H. Chen, and W. Song (2006)
FASEB J 20, 1361-1368
   Abstract »    Full Text »    PDF »
BACE2, as a novel APP {theta}-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
X. Sun, G. He, and W. Song (2006)
FASEB J 20, 1369-1376
   Abstract »    Full Text »    PDF »
Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
X. Sun, Y. Wang, H. Qing, M. A. Christensen, Y. Liu, W. Zhou, Y. Tong, C. Xiao, Y. Huang, S. Zhang, et al. (2005)
FASEB J 19, 739-749
   Abstract »    Full Text »    PDF »
Constitutional Aneuploidy in the Normal Human Brain.
S. K. Rehen, Y. C. Yung, M. P. McCreight, D. Kaushal, A. H. Yang, B. S. V. Almeida, M. A. Kingsbury, K. M. S. Cabral, M. J. McConnell, B. Anliker, et al. (2005)
J. Neurosci. 25, 2176-2180
   Abstract »    Full Text »    PDF »
A GG Nucleotide Sequence of the 3' Untranslated Region of Amyloid Precursor Protein mRNA Plays a Key Role in the Regulation of Translation and the Binding of Proteins.
E. G. M. Mbella, S. Bertrand, G. Huez, and J.-N. Octave (2000)
Mol. Cell. Biol. 20, 4572-4579
   Abstract »    Full Text »
Association of Decreased Paternal Age and Late-Onset Alzheimer's Disease: An Example of Genetic Imprinting?.
L. A. Farrer, L. A. Cupples, L. Connor, P. A. Wolf, and J. H. Growdon (1991)
Arch Neurol 48, 599-604
   Abstract »    PDF »
Natural Killer Cell Activity in Patients With Dementia of the Alzheimer Type.
S. Araga, H. Kagimoto, K. Funamoto, A. Adachi, K. Inoue, and K. Takahashi (1990)
Arch Neurol 47, 380-381
   Abstract »    PDF »
Amyloid beta protein enhances the survival of hippocampal neurons in vitro.
J. Whitson, D. Selkoe, and C. Cotman (1989)
Science 243, 1488-1490
   Abstract »    PDF »
The Molecular Genetic Revolution: Its Impact on Clinical Neurology.
C. S. Payne and A. D. Roses (1988)
Arch Neurol 45, 1366-1376
   Abstract »    PDF »
Biologic Markers, Genetics, and Alzheimer's Disease.
G. W. Small and D. A. Greenberg (1988)
Arch Gen Psychiatry 45, 945-947
   Abstract »    PDF »
Role of Alzheimer's protein is tangled.
J. Mark (1987)
Science 238, 1352-1353
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)